Rectal insertion device
Latest AstraZeneca AB Patents:
- Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
- Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
- Dendrimer formulations
- GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
- PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
Description
FIG. 1 is a perspective view of the rectal insertion device according to the present invention.
FIG. 2 is an end elevation view of the rectal insertion device.
FIG. 3 is an opposite end elevation view of the rectal insertion device; and,
FIG. 4 is a side elevation view of the rectal insertion device.
Claims
The ornamental design for a rectal insertion device, as shown.
Referenced Cited
Patent History
Patent number: D443930
Type: Grant
Filed: Mar 31, 2000
Date of Patent: Jun 19, 2001
Assignee: AstraZeneca AB (Sodertalje)
Inventor: Daniel Nestenborg (Brännö)
Primary Examiner: Ian Simmons
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/121,112
Type: Grant
Filed: Mar 31, 2000
Date of Patent: Jun 19, 2001
Assignee: AstraZeneca AB (Sodertalje)
Inventor: Daniel Nestenborg (Brännö)
Primary Examiner: Ian Simmons
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/121,112
Classifications
Current U.S. Class:
Body Cavity Insertion (e.g., Tampon Or Suppository Applicator, Etc.) (27) (D24/141);
Conduit Or Nozzle (e.g., Syringe, Cannula, Catheter, Etc.) (8) (D24/112);
Speculum, Dilator Or Retractor (25) (D24/135)
International Classification: 2402;
International Classification: 2402;